These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9779795)

  • 21. Empirical free energy as a target function in docking and design: application to HIV-1 protease inhibitors.
    King BL; Vajda S; DeLisi C
    FEBS Lett; 1996 Apr; 384(1):87-91. PubMed ID: 8797810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
    J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease.
    Whitfield TW; Ragland DA; Zeldovich KB; Schiffer CA
    J Chem Theory Comput; 2020 Feb; 16(2):1284-1299. PubMed ID: 31877249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations.
    Jenwitheesuk E; Samudrala R
    BMC Struct Biol; 2003 Apr; 3():2. PubMed ID: 12675950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
    Appadurai R; Senapati S
    Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
    Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
    Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
    [No Abstract]   [Full Text] [Related]  

  • 29. Adaptability and flexibility of HIV-1 protease.
    Kumar M; Hosur MV
    Eur J Biochem; 2003 Mar; 270(6):1231-9. PubMed ID: 12631281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein-ligand docking with multiple flexible side chains.
    Zhao Y; Sanner MF
    J Comput Aided Mol Des; 2008 Sep; 22(9):673-9. PubMed ID: 18034309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.
    Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D
    J Med Chem; 1994 Aug; 37(17):2664-77. PubMed ID: 8064795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
    Chetty S; Bhakat S; Martin AJ; Soliman ME
    J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fragment-Based flexible ligand docking by evolutionary optimization.
    Budin N; Majeux N; Caflisch A
    Biol Chem; 2001 Sep; 382(9):1365-72. PubMed ID: 11688719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.
    Chang MW; Lindstrom W; Olson AJ; Belew RK
    J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
    Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
    Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
    Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
    J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
    Chen X; Weber IT; Harrison RW
    J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.